Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Antigen-mediated regulation in monoclonal gammopathies and myeloma
Shiny Nair, … , Eric Meffre, Madhav V. Dhodapkar
Shiny Nair, … , Eric Meffre, Madhav V. Dhodapkar
Published April 19, 2018
Citation Information: JCI Insight. 2018;3(8):e98259. https://doi.org/10.1172/jci.insight.98259.
View: Text | PDF
Research Article Oncology

Antigen-mediated regulation in monoclonal gammopathies and myeloma

  • Text
  • PDF
Abstract

A role for antigen-driven stimulation has been proposed in the pathogenesis of monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) based largely on the binding properties of monoclonal Ig. However, insights into antigen binding to clonal B cell receptors and in vivo responsiveness of the malignant clone to antigen-mediated stimulation are needed to understand the role of antigenic stimulation in tumor growth. Lysolipid-reactive clonal Ig were detected in Gaucher disease (GD) and some sporadic gammopathies. Here, we show that recombinant Ig (rIg) cloned from sort-purified single tumor cells from lipid-reactive sporadic and GD-associated gammopathy specifically bound lysolipids. Liposome sedimentation and binding assays confirmed specific interaction of lipid-reactive monoclonal Ig with lysolipids. The clonal nature of lysolipid-binding Ig was validated by protein sequencing. Gene expression profiling and cytogenetic analyses from 2 patient cohorts showed enrichment of nonhyperdiploid tumors in lipid-reactive patients. In vivo antigen-mediated stimulation led to an increase in clonal Ig and plasma cells (PCs) in GD gammopathy and also reactivated previously suppressed antigenically related nonclonal PCs. These data support a model wherein antigenic stimulation mediates an initial polyclonal phase, followed by evolution of monoclonal tumors enriched in nonhyperdiploid genomes, responsive to underlying antigen. Targeting underlying antigens may therefore prevent clinical MM.

Authors

Shiny Nair, Joel Sng, Chandra Sekhar Boddupalli, Anja Seckinger, Marta Chesi, Mariateresa Fulciniti, Lin Zhang, Navin Rauniyar, Michael Lopez, Natalia Neparidze, Terri Parker, Nikhil C. Munshi, Rachael Sexton, Bart Barlogie, Robert Orlowski, Leif Bergsagel, Dirk Hose, Richard A. Flavell, Pramod K. Mistry, Eric Meffre, Madhav V. Dhodapkar

×

Figure 4

Genetic features of tumor cells in lipid-reactive gammopathy.

Options: View larger image (or click on image) Download as PowerPoint
Genetic features of tumor cells in lipid-reactive gammopathy.
(A) Pie ch...
(A) Pie charts compare the percentages of different molecular classification (MC) subgroups between lipid-reactive and non–lipid-reactive patients. Data shown are cumulative data from cohort 1 (n = 76) and 2 (n = 274) (***P < 0.001,*P < 0.05, Fisher’s exact test). (B) Bar graph shows comparison of percentage of patients based on the detection of high-risk GEP signatures and cytogenetic abnormalities in tumor cells between non–lipid-reactive and lipid-reactive patients. Data are from patients in cohort 2 (n = 274) with available cytogenetics and GEP signatures (*P < 0.05, Fisher’s exact test). HY, hyperdiploid; LB, low bone; MF, Maf; MS, MMSET; PR, proliferation; CD, cyclin D.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts